at this very time 22 mill is a ‘lifesaver’ in one sense, sp steady with a nice ‘premium’ to pre suspension sp, dilution would have seen the sp at what level?
quite right in seeing the big picture, it equates to two quarters of cash burn, albeit take into account the potential extra 12 mill windfall.
you may be quite right on your gut feelings, of a future potential announcement, TAVR deal may be the catalyst to turn around the fortunes of this company, current market sp most definitely indicative of a wait and watch future events unfold.
TAVR deal should certainly change sentiment, minus of perhaps giving the Lions share to a partner, most positive of not having to fund R&D from future revenue, add into the mix those funds then advancing the Adapt IP tech.
@linebreaker, most flattered, and also MOST underserving of even being mentioned in the same breath as Tolstoy, however disparagingly!
ps; Wass a reply to wessomart.
- Forums
- ASX - By Stock
- AVR
- Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-139
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$11.72 |
Change
-0.080(0.68%) |
Mkt cap ! $249.4M |
Open | High | Low | Value | Volume |
$11.85 | $11.90 | $11.50 | $40.90K | 3.511K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10 | $11.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.71 | 509 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 67 | 11.630 |
1 | 86 | 11.620 |
1 | 516 | 11.510 |
2 | 543 | 11.500 |
1 | 500 | 11.400 |
Price($) | Vol. | No. |
---|---|---|
11.850 | 475 | 1 |
11.890 | 1 | 1 |
11.900 | 231 | 1 |
11.950 | 60 | 1 |
12.000 | 2315 | 5 |
Last trade - 10.15am 05/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |